Clinical Trials Logo

Clinical Trial Details — Status: Active, not recruiting

Administrative data

NCT number NCT05047237
Other study ID # IRB00076190
Secondary ID
Status Active, not recruiting
Phase N/A
First received
Last updated
Start date October 29, 2021
Est. completion date April 2025

Study information

Verified date October 2023
Source Wake Forest University Health Sciences
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

The purpose of this research is to explore whether a pharmacist-led diabetes management program can help optimize diabetes care for older adults. Participation in this study will involve meeting with a pharmacist who works with subjects' doctors, getting some routine bloodwork typical for people with diabetes, and potentially adjusting the subject's diabetes medications to reach American Diabetes Association guidelines. This study aims to bring older adults with diabetes whose measurements and medications are different from the guidelines of the American Diabetes Association into guidelines-based ranges.


Description:

This study is a pragmatic pilot study assessing the feasibility and acceptability, and preliminary impact of a pharmacist-led care pathway to align patient care with guidelines for type 2 diabetes mellitus (T2DM) management in frail older adults, leveraging existing resources and pathways of care led by Clinical Prescribing Pharmacists. Eligible participants will be identified from the Electronic Health Record (EHR). Research staff will then approach the primary care physicians for identified patients to confirm that patients are appropriate for the intervention, as determined by the primary care physician (PCP). Patients will then be contacted both by letter and phone call, and invited to participate in the pharmacist-led pathway. Telephonic informed consent will be obtained. Outcomes for all participants will be accessed passively via the EHR. The study team hypothesizes that patients who go through the pharmacist-led primary care intervention will be more likely to have guideline-concordant medical therapy as compared with an EHR-based control group. Also, the study team believes that the intervention will reach at least 50% of those referred by their physicians to participate, the median number of outpatient visits will be three or less, and that the intervention will require a total of <3 hours for pharmacists and patients across the 3-month intervention period. In addition, the study team expects patients, physicians, and pharmacists will report the intervention is feasible, acceptable, appropriate, and high-value. Lastly, the study team believes that the intervention group will have a lower mortality than the comparison group.


Recruitment information / eligibility

Status Active, not recruiting
Enrollment 100
Est. completion date April 2025
Est. primary completion date November 2024
Accepts healthy volunteers No
Gender All
Age group 65 Years and older
Eligibility Inclusion Criteria: - Attributed to a Atrium Health Wake Forest Baptist-affiliated Accountable Care Organization - At least 2 consecutive International Classification of Diseases 10th Revision (ICD-10) codes for type two diabetes mellitus in the prior 2 years - Has a calculable Electronic Frailty Index (eFI) score >0.21 - A glycosylated hemoglobin (HbA1c) value <7.5% in the prior 2 years - Currently taking a sulfonylurea or insulin for Type 2 Diabetes Mellitus (T2DM) Exclusion Criteria: - Moderate to severe hearing loss (due to phone interventions) - Diagnosed Alzheimer's disease or related dementia (unable to participate) - Non-English speaking (not all pharmacists speak a second language; subtleties may not be conveyed effectively) - No phone number available for patient (follow up contacts will be by telehealth or phone

Study Design


Related Conditions & MeSH terms


Intervention

Behavioral:
Pharmacist-Led Optimization Intervention
Educational information mailed to participants and up to three pharmacist visits.

Locations

Country Name City State
United States Atrium Health Wake Forest Baptist Health Winston-Salem North Carolina

Sponsors (1)

Lead Sponsor Collaborator
Wake Forest University Health Sciences

Country where clinical trial is conducted

United States, 

Outcome

Type Measure Description Time frame Safety issue
Primary Proportion of subjects who Achieve Glycosylated Hemoglobin (HbA1c) values Proportion of subjects who achieve target value of HbA1c >7.5% Month 6
Primary Change in HbA1c From Baseline through Month 6
Primary Random Glucose Measurements The study team will track any glucose measurements obtained between initial enrollment and 6-12 months follow up after completion of the intervention, up until a total of 12 months after initial enrollment. This will be reported as a glucose trajectory. From Baseline through Month 12
Primary Estimated Change in Out-of-Pocket Costs Change in diabetes medication cost From Baseline through Month 6
Primary Point estimates of Feasibility Measures: Participation/Reach The proportion of those referred who chose to participate Month 6
Primary Point estimates of Feasibility Measures: Number Contacted/Reach Total number of subjects contacted Month 6
Primary Point estimates of Feasibility Measures: Number at Risk/Reach Total number of patients who meet inclusion/exclusion criteria at each site Month 6
Primary Feasibility Measures: Effort Required to Enroll-Number Calls Number of calls to enroll Month 6
Primary Feasibility Measures: Effort Required to Enroll-Average Call Duration Duration of calls to enroll in minutes. Month 6
Primary Point estimates of Feasibility Measure-Number of Visits Mean and median number of visits with the pharmacist before glucose levels are met. Month 12
Primary Point estimates of Feasibility Measures: Time Time until achieved medication goal per patient will be reported. An achieved medication goal is the following: HbA1c <8 while taking no sulfonylurea or insulin, or HbA1c between 7.5-8 on sulfonylurea or insulin (these would both meet guidelines-based care. Month 12
Secondary Rate of Emergency Department Visits and Hospitalizations Using EHR and Patient Ping, the number of contacts with the Emergency Department (ED) and hospitals (composite) Baseline through Month 18
Secondary Number of Hypoglycemic Events Requiring Medical Assistance Events defined as per action to control cardiovascular risk in diabetes (ACCORD) trial, as hypoglycemic episodes requiring hospitalization or care in an emergency department. Time Frame: Baseline through Month 18
Secondary Number of Injurious Falls Identified by International Classification of Diseases-10th Revision (ICD-10) diagnostic codes; defined as per systolic blood pressure intervention trial (SPRINT) as falls requiring hospitalization or care in an emergency department. Baseline through Month 18
Secondary Mortality Number of people who die as found in EHR and North Carolina (NC) death registry Baseline through Month 18
Secondary Implementation Metric--Feasibility Feasibility (FIM): This is a questionnaire that helps determine feasibility of the intervention. Score ranges from 4-20, with a higher score meaning the participant feels the intervention is more feasible. Baseline through Month 18
Secondary Implementation Metric-- Acceptability This is a questionnaire that helps determine acceptability of the intervention. Score ranges from 4-20, with a higher score meaning the participant feels the intervention is more acceptable. Baseline through Month 18
Secondary Implementation Metric-- Appropriateness This is a questionnaire that helps determine appropriateness of the intervention. Score ranges from 4-20, with a higher score meaning the participant feels the intervention is more appropriate. Baseline through Month 18
Secondary Implementation Metric- Value Three questions will be coded and analyzed through qualitative analysis. The study team will code comments by hand using content analysis and grounded theory. Baseline through Month 18
See also
  Status Clinical Trial Phase
Completed NCT05594446 - Morphometric Study of the Legs and Feet of Diabetic Patients in Order to Collect Data Intended to be Used to Measure by Dynamometry the Pressures Exerted by Several Medical Compression Socks at the Level of the Forefoot
Completed NCT03975309 - DHS MIND Metabolomics
Completed NCT01855399 - Technologically Enhanced Coaching: A Program to Improve Diabetes Outcomes N/A
Completed NCT01819129 - Efficacy and Safety of FIAsp Compared to Insulin Aspart in Combination With Insulin Glargine and Metformin in Adults With Type 2 Diabetes Phase 3
Recruiting NCT04984226 - Sodium Bicarbonate and Mitochondrial Energetics in Persons With CKD Phase 2
Recruiting NCT05007990 - Caregiving Networks Across Disease Context and the Life Course
Active, not recruiting NCT04420936 - Pragmatic Research in Healthcare Settings to Improve Diabetes and Obesity Prevention and Care for Our Program N/A
Recruiting NCT03549559 - Imaging Histone Deacetylase in the Heart N/A
Completed NCT04903496 - Clinical Characteristics and Disease Burden of Diabetic Patients Based on Tianjin Regional Database
Completed NCT01437592 - Investigating the Pharmacokinetic Properties of NN1250 in Healthy Chinese Subjects Phase 1
Completed NCT01696266 - An International Survey on Hypoglycaemia Among Insulin-treated Patients With Diabetes
Completed NCT04082585 - Total Health Improvement Program Research Project
Completed NCT03390179 - Hyperglycemic Response and Steroid Administration After Surgery (DexGlySurgery)
Not yet recruiting NCT05029804 - Effect of Walking Exercise Training on Adherence to Disease Management and Metabolic Control in Diabetes N/A
Recruiting NCT05294822 - Autologous Regenerative Islet Transplantation for Insulin-dependent Diabetes N/A
Completed NCT04427982 - Dance and Diabetes/Prediabetes Self-Management N/A
Completed NCT02356848 - STEP UP to Avert Amputation in Diabetes N/A
Completed NCT03292185 - A Trial to Investigate the Single Dose Pharmacokinetics of Insulin Degludec/Liraglutide Compared With Insulin Degludec and Liraglutide in Healthy Chinese Subjects Phase 1
Active, not recruiting NCT05477368 - Examining the Feasibility of Prolonged Ketone Supplement Drink Consumption in Adults With Type 2 Diabetes N/A
Completed NCT04496401 - PK Study in Diabetic Transplant récipients : From Twice-daily Tacrolimus to Once-daily Extended-release Tacrolimus Phase 4